Longitudinal effects of gantenerumab treatment on amyloid‐PET‐derived perfusion estimates in an early AD population
Erica Silvestri, Matteo Tonietto, Susanna Gobbi, Marzia Antonella Scelsi, Gregory Klein · 2025
Read Longitudinal effects of gantenerumab treatment on amyloid‐PET‐derived perfusion estimates in an early AD population by Erica Silvestri, Matteo Tonietto, Susanna Gobbi, Marzia Antonella Scelsi, Gregory Klein (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713918.txt.
Description
Erica Silvestri and four co-authors ask whether a drug that clears amyloid also changes blood flow measures read from the same brain scan. Amyloid PET scans can report both amyloid load and a flow signal, taken from early frames or from full modeling. Their 2025 study follows people with early Alzheimer's disease treated with gantenerumab, an antibody that removes amyloid. A worry is that the drug's effect on amyloid could distort the flow estimates drawn from the tracer.
The team compared simple early-frame ratios with the modeled flow values over time. They also tested whether amyloid itself biases the simple measure. Clean flow readouts matter because flow tracks disease stage and treatment response. The study helps labs use one scan for two jobs without fooling themselves.
Catalog record
| CREATOR | Erica Silvestri, Matteo Tonietto, Susanna Gobbi, Marzia Antonella Scelsi, Gregory Klein |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |